Premium
Bavarian Nordic AS (PK) (BVNRY)
USOTC
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
EDISON EQUITY RESEARCH: BAVARIAN NORDIC – ADR OUTLOOK The BMS and J&J deals, and continued Imvamune related income have provided Bavarian Nordic with validation of its vaccine...
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments;...
EDISON EQUITY RESEARCH: BAVARIAN NORDIC - STRATEGIC EBOLDA DEAL FILLS 2015 REVENUE GAP Bavarian Nordic’s $187m exclusive global licensing and supply deal for its development Ebola vaccine...
KVISTGAARD, Denmark, July 24, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of...
KVISTGAARD, Denmark, May 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Paul Chaplin, Ph.D. has been appointed new President and CEO of the Company...
KVISTGAARD, Denmark, May 15, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today two papers featuring the combination of the Company's proprietary cancer...
KVISTGAARD, Denmark, May 14, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first quarter of 2014. Revenue...
KVISTGAARD, Denmark, April 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2...
KVISTGAARD, Denmark, March 19, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK...
Alliance For Biosecurity Elects Chief Executive Officers Of Bavarian Nordic And Elusys Therapeutics As New Co-Chairs Leadership Team Will Advance Industry Efforts Supporting the Development of...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.05 | -0.558659217877 | 8.95 | 8.964 | 8.34 | 9427 | 8.80213759 | DR |
| 4 | -0.29 | -3.1556039173 | 9.19 | 9.445 | 8.34 | 19255 | 9.05822762 | DR |
| 12 | -2.285 | -20.4291461779 | 11.185 | 11.185 | 7.89 | 25339 | 9.46745513 | DR |
| 26 | 0.4599 | 5.44898757124 | 8.4401 | 15.11 | 7.89 | 56938 | 12.09331847 | DR |
| 52 | 0.35 | 4.09356725146 | 8.55 | 15.11 | 6.86 | 32101 | 11.76650726 | DR |
| 156 | -5.1395 | -36.6074290395 | 14.0395 | 20.67 | 5.85 | 47398 | 13.24291119 | DR |
| 260 | 0.56 | 6.71462829736 | 8.34 | 20.67 | 5.04 | 38271 | 13.24007423 | DR |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
